IGM Biosciences (IGMS)

• Market cap: $71.1M
• 1 day: -0.83%
• 5 days: -2.46%
• 1 month: -13.77%
• 3 months: -81.72%
• 6 months: -92.56%
• Year to date: -80.84%
• 1 year: -88.37%
• 5 years: -97.70%
• 10 years: -95.10%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

220% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 5

68% more call options, than puts

Call options by funds: $377K | Put options by funds: $224K

37% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 19

15% more funds holding

Funds holding: 72 [Q3] → 83 (+11) [Q4]

0.07% more ownership

Funds ownership: 63.54% [Q3] → 63.61% (+0.07%) [Q4]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

63% less capital invested

Capital invested by funds: $357M [Q3] → $133M (-$224M) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $1.50 26% upside
• Avg. target: $2 68% upside
• High target: $2.50 110% upside

5 analyst ratings

• positive: 0 0%
• neutral: 5 100%
• negative: 0 0%

Jefferies Roger Song 24% 1-year accuracy 4 / 17 met price target	68% upside $2	Hold Downgraded	10 Jan 2025
Truist Securities Asthika Goonewardene 24% 1-year accuracy 6 / 25 met price target	68% upside $2	Hold Maintained	10 Jan 2025
Stifel Stephen Willey 32% 1-year accuracy 6 / 19 met price target	110% upside $2.50	Hold Downgraded	10 Jan 2025
RBC Capital Brian Abrahams 17% 1-year accuracy 12 / 72 met price target	26% upside $1.50	Sector Perform Downgraded	10 Jan 2025
BMO Capital Etzer Darout 21% 1-year accuracy 7 / 34 met price target	68% upside $2	Market Perform Downgraded	10 Jan 2025